We are live on ! Find out more
VYNT

Vyant Bio, Inc. Common Stock
VYNT

Delisted

VYNT was delisted on the 12th of May, 2023.

Back to rankings

17 hedge funds and large institutions have $222K invested in Vyant Bio, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

35% less funds holding

Funds holding: 26 → 17 (-9)

75% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 12

77% less capital invested

Capital invested by funds: $949K → $222K (-$727K)

Holders
17
Holders Change
-9
Holders Change %
-34.62%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
7
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$27.5K
2
Renaissance Technologies
Renaissance Technologies
New York
+$16.5K
3
VF
Virtu Financial
New York
+$13.7K
4
Citadel Advisors
Citadel Advisors
Florida
+$11.2K
5
UBS Group
UBS Group
Switzerland
+$3.51K

Top Sellers

Rank Fund Capital Flow
1
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$113K
2
Northern Trust
Northern Trust
Illinois
-$24K
3
JSC
Jackson Square Capital
California
-$17K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$12K
5
TSS
Two Sigma Securities
New York
-$12K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
26
Carlson Capital Management
Minnesota
– -$7K -2,360 Closed
Mariner
27
Mariner
Kansas
– -$6K -2,055 Closed
Royal Bank of Canada
28
Royal Bank of Canada
Ontario, Canada
– +$5 +3 New
1
2

VYNT Hedge Fund Activity: Q4 2022 in Review

17 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q4 2022, worth a combined $222K — down 77% from $949K a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of VYNT and 3 opened new positions — a net loss of 9 holders — while 7 trimmed existing stakes and 5 added.

The largest buyer was HRT Financial, opening a new position worth an estimated $27.5K. The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $113K sold.

  • 17 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q4 2022, down from 26 in Q3 2022.
  • Funds reported $222K of Vyant Bio, Inc. Common Stock stock for Q4 2022, down 77% quarter-over-quarter.
  • 3 funds opened new Vyant Bio, Inc. Common Stock positions in Q4 2022 and 12 closed out, a net change of -9 holders.
  • The largest Vyant Bio, Inc. Common Stock buyer in Q4 2022 was HRT Financial, an estimated $27.5K added.
  • The largest Vyant Bio, Inc. Common Stock seller in Q4 2022 was CAPTRUST Financial Advisors, an estimated $113K sold.

Based on aggregated 13F filings for Q4 2022.